Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
08:59pm, Monday, 22'nd Nov 2021 Intrado Digital Media
Company Announcement
Genmab A/S (OTCMKTS:GNMSF) Short Interest Update
12:26am, Sunday, 21'st Nov 2021 Dakota Financial News
Genmab A/S (OTCMKTS:GNMSF) was the recipient of a significant drop in short interest during the month of October. As of October 29th, there was short interest totalling 11,300 shares, a drop of 33.5% from the October 14th total of 17,000 shares. Based on an average trading volume of 1,600 shares, the days-to-cover ratio is currently []
Genmab A/S (GMAB) Q3 2021 Earnings Call Transcript
08:00pm, Saturday, 20'th Nov 2021 The Motley Fool
GMAB earnings call for the period ending September 30, 2021.
Genmab Share Slump Is Buying Opportunity, Nordea Says
09:40am, Wednesday, 17'th Nov 2021 FinanzNachrichten
(PLX AI) - Genmab''s recent share slump is a buying opportunity, analysts at Nordea said, maintaining an unchanged price target of DKK 3,191. Investors should add to positions ahead of the J&J Phar
Genmab A/S (NASDAQ:GMAB) Forecasted to Post FY2021 Earnings of $0.71 Per Share
07:12am, Wednesday, 17'th Nov 2021 Dakota Financial News
Genmab A/S (NASDAQ:GMAB) Jefferies Financial Group lifted their FY2021 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued to investors on Thursday, November 11th. Jefferies Financial Group analyst P. Welford now forecasts that the company will post earnings per share of $0.71 for the year, up from their []
Genmab A/S (NASDAQ:GMAB) Expected to Post Quarterly Sales of $431.78 Million
02:32am, Wednesday, 17'th Nov 2021 Dakota Financial News
Wall Street brokerages expect Genmab A/S (NASDAQ:GMAB) to announce $431.78 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Genmab A/Ss earnings. The lowest sales estimate is $379.00 million and the highest is $522.36 million. Genmab A/S posted sales of $327.51 million in the same quarter last year, which []
Y Intercept Hong Kong Ltd Sells 3,178 Shares of Genmab A/S (NASDAQ:GMAB)
12:16pm, Tuesday, 16'th Nov 2021 Dakota Financial News
Y Intercept Hong Kong Ltd reduced its stake in Genmab A/S (NASDAQ:GMAB) by 29.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,722 shares of the companys stock after selling 3,178 shares during the quarter. Y Intercept Hong Kong Ltds []
Truist Securiti Equities Analysts Increase Earnings Estimates for Genmab A/S (NASDAQ:GMAB)
07:02am, Tuesday, 16'th Nov 2021 Dakota Financial News
Genmab A/S (NASDAQ:GMAB) Stock analysts at Truist Securiti lifted their FY2021 earnings estimates for shares of Genmab A/S in a research report issued to clients and investors on Thursday, November 11th. Truist Securiti analyst A. Goonewardene now expects that the company will post earnings per share of $0.67 for the year, up from their []
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2021 Results - Earnings Call Transcript
04:47pm, Wednesday, 10'th Nov 2021
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2021 Results - Earnings Call Transcript
Genmab to Present at Jefferies Virtual London Healthcare Conference
10:19am, Wednesday, 03'rd Nov 2021
Media Release Copenhagen, Denmark, November 0 3 , 20 2 1 Genmab A/S ( Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will take part in a fireside chat at the Jefferies Virtual
Grant of Restricted Stock Units and Warrants to Employees in Genmab
02:55pm, Thursday, 07'th Oct 2021
Company Announcement
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
02:15pm, Friday, 01'st Oct 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NM
Capital Increase in Genmab as a Result of Employee Warrant Exercise
02:22pm, Tuesday, 21'st Sep 2021
Company Announcement
FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer
08:15am, Tuesday, 21'st Sep 2021
The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S' (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent o
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
06:47am, Monday, 20'th Sep 2021
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV
